Summary
AbbVie Inc. (ABBV) has filed an 8-K report detailing the completion of a significant debt financing transaction on September 26, 2019. The company successfully sold €1.4 billion in senior notes, split between €750 million of 0.750% notes due 2027 and €650 million of 1.250% notes due 2031. This issuance was conducted under a previously filed shelf registration statement and prospectus supplement. The primary purpose of this debt issuance is to redeem, satisfy, and discharge AbbVie's outstanding €1.4 billion of 0.375% senior notes due 2019. Any remaining proceeds, after accounting for any premium and accrued interest on the redeemed notes, will be used for general corporate purposes. This move indicates AbbVie's strategic management of its debt obligations and its approach to optimizing its capital structure.
Key Highlights
- 1AbbVie completed the sale of €1.4 billion in senior notes on September 26, 2019.
- 2The issuance consists of two tranches: €750 million of 0.750% senior notes due 2027 and €650 million of 1.250% senior notes due 2031.
- 3The net proceeds are intended to redeem AbbVie's €1.4 billion of 0.375% senior notes due 2019.
- 4This transaction is aimed at refinancing existing debt and potentially freeing up cash for general corporate purposes.
- 5The notes are unsecured, unsubordinated obligations of AbbVie, ranking equally with other unsecured debt.
- 6The transaction was executed under a shelf registration statement and prospectus supplement filed earlier with the SEC.